Global Neuromuscular Blocking Agent (NMBA) Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Market Overview

• 1.1 Neuromuscular Blocking Agent (NMBA) Introduction
• 1.2 Market Analysis by Type
  • 1.2.1 Depolarizing
  • 1.2.2 Non-depolarizing
• 1.3 Market Analysis by Applications
  • 1.3.1 Hospital
  • 1.3.2 Clinic
  • 1.3.3 Pharmacy
  • 1.3.4 Others
• 1.4 Market Analysis by Regions
  • 1.4.1 North America (United States, Canada and Mexico)
    • 1.4.1.1 United States Market States and Outlook (2014-2024)
    • 1.4.1.2 Canada Market States and Outlook (2014-2024)
    • 1.4.1.3 Mexico Market States and Outlook (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
    • 1.4.2.1 Germany Market States and Outlook (2014-2024)
    • 1.4.2.2 France Market States and Outlook (2014-2024)
    • 1.4.2.3 UK Market States and Outlook (2014-2024)
    • 1.4.2.4 Russia Market States and Outlook (2014-2024)
    • 1.4.2.5 Italy Market States and Outlook (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
    • 1.4.3.1 China Market States and Outlook (2014-2024)
    • 1.4.3.2 Japan Market States and Outlook (2014-2024)
    • 1.4.3.3 Korea Market States and Outlook (2014-2024)
    • 1.4.3.4 India Market States and Outlook (2014-2024)
    • 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
  • 1.4.4 South America, Middle East and Africa
    • 1.4.4.1 Brazil Market States and Outlook (2014-2024)
    • 1.4.4.2 Egypt Market States and Outlook (2014-2024)
    • 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
    • 1.4.4.4 South Africa Market States and Outlook (2014-2024)
    • 1.4.4.5 Turkey Market States and Outlook (2014-2024)
• 1.5 Market Dynamics
  • 1.5.1 Market Opportunities
  • 1.5.2 Market Risk
  • 1.5.3 Market Driving Force

2 Manufacturers Profiles

• 2.1 AbbVie
  • 2.1.1 Business Overview
  • 2.1.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 AbbVie Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Somerset Therapeutics
  • 2.2.1 Business Overview
  • 2.2.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Hengrui Pharmaceutical
  • 2.3.1 Business Overview
  • 2.3.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 GlaxoSmithKline
  • 2.4.1 Business Overview
  • 2.4.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Sandoz
  • 2.5.1 Business Overview
  • 2.5.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Sandoz Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Pfizer
  • 2.6.1 Business Overview
  • 2.6.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Pfizer Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Shanghai Pharmaceuticals
  • 2.7.1 Business Overview
  • 2.7.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Fresenius Kabi
  • 2.8.1 Business Overview
  • 2.8.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Abbott Laboratories
  • 2.9.1 Business Overview
  • 2.9.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Guike Pharmaceutical
  • 2.10.1 Business Overview
  • 2.10.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Themis Medicare
  • 2.11.1 Business Overview
  • 2.11.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Nanjing King-Friend
  • 2.12.1 Business Overview
  • 2.12.2 Neuromuscular Blocking Agent (NMBA) Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

3 Global Neuromuscular Blocking Agent (NMBA) Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

• 3.1 Global Neuromuscular Blocking Agent (NMBA) Sales and Market Share by Manufacturer (2017-2018)
• 3.2 Global Neuromuscular Blocking Agent (NMBA) Revenue and Market Share by Manufacturer (2017-2018)
• 3.3 Market Concentration Rate
  • 3.3.1 Top 3 Neuromuscular Blocking Agent (NMBA) Manufacturer Market Share in 2018
  • 3.3.2 Top 6 Neuromuscular Blocking Agent (NMBA) Manufacturer Market Share in 2018
• 3.4 Market Competition Trend

4 Global Neuromuscular Blocking Agent (NMBA) Market Analysis by Regions

• 4.1 Global Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Market Share by Regions
  • 4.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales and Market Share by Regions (2014-2019)
  • 4.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue and Market Share by Regions (2014-2019)
• 4.2 North America Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 4.3 Europe Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 4.5 South America Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)

5 North America Neuromuscular Blocking Agent (NMBA) by Country

• 5.1 North America Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Market Share by Country
  • 5.1.1 North America Neuromuscular Blocking Agent (NMBA) Sales and Market Share by Country (2014-2019)
  • 5.1.2 North America Neuromuscular Blocking Agent (NMBA) Revenue and Market Share by Country (2014-2019)
• 5.2 United States Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 5.3 Canada Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 5.4 Mexico Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)

6 Europe Neuromuscular Blocking Agent (NMBA) by Country

• 6.1 Europe Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Market Share by Country
  • 6.1.1 Europe Neuromuscular Blocking Agent (NMBA) Sales and Market Share by Country (2014-2019)
  • 6.1.2 Europe Neuromuscular Blocking Agent (NMBA) Revenue and Market Share by Country (2014-2019)
• 6.2 Germany Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 6.3 UK Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 6.4 France Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 6.5 Russia Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 6.6 Italy Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)

7 Asia-Pacific Neuromuscular Blocking Agent (NMBA) by Country

• 7.1 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Market Share by Country
  • 7.1.1 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales and Market Share by Country (2014-2019)
  • 7.1.2 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue and Market Share by Country (2014-2019)
• 7.2 China Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 7.3 Japan Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 7.4 Korea Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 7.5 India Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 7.6 Southeast Asia Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)

8 South America Neuromuscular Blocking Agent (NMBA) by Country

• 8.1 South America Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Market Share by Country
  • 8.1.1 South America Neuromuscular Blocking Agent (NMBA) Sales and Market Share by Country (2014-2019)
  • 8.1.2 South America Neuromuscular Blocking Agent (NMBA) Revenue and Market Share by Country (2014-2019)
• 8.2 Brazil Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 8.3 Argentina Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 8.4 Colombia Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)

9 Middle East and Africa Neuromuscular Blocking Agent (NMBA) by Countries

• 9.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Market Share by Country
  • 9.1.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales and Market Share by Country (2014-2019)
  • 9.1.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue and Market Share by Country (2014-2019)
• 9.2 Saudi Arabia Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 9.3 Turkey Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 9.4 Egypt Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 9.5 Nigeria Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)
• 9.6 South Africa Neuromuscular Blocking Agent (NMBA) Sales and Growth Rate (2014-2019)

10 Global Neuromuscular Blocking Agent (NMBA) Market Segment by Type

• 10.1 Global Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Market Share by Type (2014-2019)
  • 10.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales and Market Share by Type (2014-2019)
  • 10.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue and Market Share by Type (2014-2019)
• 10.2 Depolarizing Sales Growth and Price
  • 10.2.1 Global Depolarizing Sales Growth (2014-2019)
  • 10.2.2 Global Depolarizing Price (2014-2019)
• 10.3 Non-depolarizing Sales Growth and Price
  • 10.3.1 Global Non-depolarizing Sales Growth (2014-2019)
  • 10.3.2 Global Non-depolarizing Price (2014-2019)

11 Global Neuromuscular Blocking Agent (NMBA) Market Segment by Application

• 11.1 Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2014-2019)
• 11.2 Hospital Sales Growth (2014-2019)
• 11.3 Clinic Sales Growth (2014-2019)
• 11.4 Pharmacy Sales Growth (2014-2019)
• 11.5 Others Sales Growth (2014-2019)

12 Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2024)

• 12.1 Global Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Growth Rate (2019-2024)
• 12.2 Neuromuscular Blocking Agent (NMBA) Market Forecast by Regions (2019-2024)
  • 12.2.1 North America Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2024)
  • 12.2.2 Europe Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2024)
  • 12.2.3 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2024)
  • 12.2.4 South America Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2024)
  • 12.2.5 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Forecast (2019-2024)
• 12.3 Neuromuscular Blocking Agent (NMBA) Market Forecast by Type (2019-2024)
  • 12.3.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Type (2019-2024)
  • 12.3.2 Global Neuromuscular Blocking Agent (NMBA) Market Share Forecast by Type (2019-2024)
• 12.4 Neuromuscular Blocking Agent (NMBA) Market Forecast by Application (2019-2024)
  • 12.4.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Application (2019-2024)
  • 12.4.2 Global Neuromuscular Blocking Agent (NMBA) Market Share Forecast by Application (2019-2024)

13 Sales Channel, Distributors, Traders and Dealers

• 13.1 Sales Channel
  • 13.1.1 Direct Marketing
  • 13.1.2 Indirect Marketing
  • 13.1.3 Marketing Channel Future Trend
• 13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

• 15.1 Methodology